Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). (Q36356001)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). |
scientific article |
Statements
1 reference
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). (English)
1 reference
David M Goldenberg
1 reference
Thomas M Cardillo
1 reference
Serengulam V Govindan
1 reference
Edmund A Rossi
1 reference
Robert M Sharkey
1 reference
2 references
1 reference
1 reference
1 reference
1 reference
1 reference